Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali (LAKANA)
Mortality

About this trial
This is an interventional treatment trial for Mortality focused on measuring Mass Drug Administration, Azithromycin, Infant and Child Mortality, Infant and Child health, Infant and Child growth, Infant and Child morbidity, Antimicrobial Resistance, Feasibility, Acceptability, Safety, Cost, Inflammation, Infection
Eligibility Criteria
Inclusion Criteria:
On a cluster (village) level:
- Location within Kayes, Kita, or Koulikoro region of Mali
- Considered accessible and safe by the local health authorities and research team
- Considered non-urban by the local health authorities and research team
- Permission from community leadership
On a household level (for trial enrollment):
- Location within a cluster that is included in the study
- Verbal consent from a head of household or an adult authorized by her / him
On a child level (for receiving study medication):
- Residence in a household enrolled in the trial
- Age between 29 and 364 days
- Verbal consent from at least one caregiver
Exclusion Criteria:
On child level (for not receiving study medication):
- Weight below 3.0 kg
- Known allergy to macrolides, as judged by a caregiver report of the infant experiencing an adverse reaction after oral ingestion of medication, which was deemed likely to be a macrolide by the interviewing data collector.
Sites / Locations
- Center for Vaccine Development CVD-MaliRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Active Comparator
Active Comparator
Control
Azithromycin-biannually (Azi-biannual)
Azithromycin-quarterly
Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml / kg child weight Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of placebo mixture.
Azithromycin or placebo will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml / kg child weight Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of study drug. Azithromycin will be given at quarterly visits between January and June, and Placebo mixture will be given at quarterly visits between July and December. Azithromycin dose will be 20 mg / kg.
Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age: Single-dose of 0.5 ml (20 mg) / kg child weight. Participating households within villages allocated to this group will be visited quarterly (at 3-month intervals), for nine times. At the first eight of these visits, 1-11 month old eligible infants, for whom there is a consent for study drug provision, will be weighed and given a single dose of azithromycin.